Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401323 · ClinicalTrials.gov registry record · Phase 2
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 568
- Enrollment target
NCT00401323 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 568 participants.
The verdict
NCT00401323, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 568 participants
- Enrollment target
Study Summary
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Interventions
- DRUG cisplatin
- DRUG 5-fluorouracil (5-FU)
- DRUG docetaxel (XRP6976)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 1998-01 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401323
The ClinicalTrials.gov registry entry for NCT00401323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00401323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401323 about?
NCT00401323 is a clinical study titled "Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT00401323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 568 participants. The study started on 1998-01. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00401323?
The interventions under investigation include: cisplatin (DRUG), 5-fluorouracil (5-FU) (DRUG), docetaxel (XRP6976) (DRUG).
Who is sponsoring clinical trial NCT00401323?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.